Adverse Reactions of Drugs Containing Valeriana and Corvalol: Analysis of Spontaneous Reporting
Open Access
- 18 December 2018
- journal article
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 6 (4) , 162-173
Abstract
Valerianа officinalis rhizomes whis roots, monocomponent and complex herbal drugs based on Valerianа officinalis, and the drug Corvalol containing chemically synthesized α-bromizovalerianic acid ethyl ester (ethyl bromovalerianate) are OTC drugs and are widely used. At the same time, in the database of drug adverse effects «Pharmacovigilance» AIS Roszdravnadzor from 2009 to 2018, 147 spontaneous reports of adverse reactions were registered when taking Valeriana rhizomes whis roots and Corvalol. The aim of the study was the analisis of spontaneous reporting about adverse reactions when taking Valeriana rhizomes and roots and the multi-component drug Corvalol in the database «Pharmacovigilance» AIS Roszdravnadzor and assessment of their compliance with the information in the instructions for medical use. It was reactions from the nervous system (lethargy, drowsiness, weakness, apathy, headache, dizziness, depression of consciousness, stupor, neurotoxicity, toxic encephalopathy), from the gastrointestinal tract (nausea, bitterness in the mouth, burning of the mucous membrane, belching, heartburn, appetite disorders), cardiovascular system (tachycardia) and allergic reactions (skin itching, skin flushing, rash, maculo-papular rash, urticaria, dermatitis, cheilitis, aphthous stomatitis, angioedema) in the reports. The sedative and anxiolytic effects of the leading biologically active component of rhizomes with valerian roots, valerenic acid, are mediated through modulation of the function of type-γ-aminobutyric acid receptors A. Experimentally confirmed that the mechanism of action of valerenic acid is similar to benzodiazepine drugs, which cause of a number of reported adverse neurological reactions. However, the range of complaints from patients cited in the reports is significantly wider than in the instructions for the medical use of these drugs. There is a need for further monitoring of reports and analysis of already received data and the addition of prescribing information of Valeriana rhizomes whis roots and Corvalol for ensuring safety requirements.Keywords
This publication has 13 references indexed in Scilit:
- Comparative randomized open-label trial on efficacy and safety of Persen® and Persen® Night herbal extracts in patients with short-term insomniaNeuromuscular Diseases, 2016
- Analysis of β-Subunit-dependent GABAA Receptor Modulation and Behavioral Effects of Valerenic Acid DerivativesThe Journal of Pharmacology and Experimental Therapeutics, 2016
- COMPARATIVE ANALYSIS OF ELEMENT, CARBOHYDRATE AND AMINO ACID COMPOSITION OF VALERIANA OFFICINALIS UNDERGROUND ORGANSI.P. Pavlov Russian Medical Biological Herald, 2013
- Extract of Valerian Root (Valeriana Officinalis L.) vs. Placebo in Treatment of Obsessive-Compulsive Disorder: A Randomized Double-Blind StudyJournal of Complementary and Integrative Medicine, 2011
- The Use of Valeriana officinalis (Valerian) in Improving Sleep in Patients Who Are Undergoing Treatment for Cancer: A Phase III Randomized, Placebo-Controlled, Double-Blind Study (NCCTG Trial, N01C5)Journal of Supportive Oncology, 2011
- Valeriana officinalis root extracts have potent anxiolytic effects in laboratory ratsPhytomedicine, 2010
- Biomedically relevant chemical constituents of Valeriana officinalisJournal of Applied Biomedicine, 2010
- GABAA receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian root extractsNeuropharmacology, 2009
- Sleep improving effects of a single dose administration of a valerian/hops fluid extract. A double blind, randomized, placebo-controlled sleep-EEG study in a parallel design using the electrohypnogramZeitschrift für Phytotherapie, 2008
- Kava and Valerian in the treatment of stress‐induced insomniaPhytotherapy Research, 2001